目次

TABLE OF CONTENT

1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 KEY INCLUSIONS & EXCLUSIONS
1.3 RESEARCH SCOPE
1.3.1 SEGMENTS COVERED
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 MAJOR MARKET STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.6.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA SOURCES
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION METHODOLOGY
2.3 MARKET SHARE ESTIMATION METHODOLOGY
2.4 MARKET BREAK DOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.6.1 SCOPE RELATED LIMITATIONS
2.6.2 METHODOLOGY RELATED LIMITATIONS
2.7 RISK ASSESSMENT
2.8 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET: MARKET OVERVIEW
4.2 HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET: BY PRODUCT AND SERVICES , 2023 VS 2029
4.3 HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY MODALITY, 2023 VS 2029
4.4 GEOGRAPHIC ANALYSIS: HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY COUNTRY AND REGION (2023)
4.5 GEOGRAPHIC SNAPSHOT OF THE POINT-OF-CARE DAIGNOSTICS MARKET

5 MARKET OVERVIEW
5.1 MARKET DYNAMICS
5.1.1 MAJOR DRIVERS
5.1.2 KEY RESTRAINTS
5.1.3 KEY GROWTH OPPORTUNITIES
5.1.4 INDUSTRY-SPECIFIC CHALLENGES
5.2 REGULATORY LANDSCAPE
5.2.1 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS
5.2.2 REGULATORY TRENDS
5.3 VALUE CHAIN ANALYSIS
5.4 SUPPLY CHAIN ANALYSIS
5.5 ECOSYSTEM MARKET MAP
5.6 TECHNOLOGY ANALYSIS
5.6.1 KEY TECHNOLOGIES
5.6.2 COMPLEMENTARY TECHNOLOGIES
5.6.3 ADJACENT TECHNOLOGIES
5.7 TRADE ANALYSIS
5.8 PATENT ANALYSIS
5.8.1 PATENT PUBLICATION TRENDS FOR THE HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET
5.8.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
5.9 PORTER’S FIVE FORCE ANALYSIS
5.10 PRICING ANALYSIS
5.10.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
5.10.2 AVERAGE SELLING PRICE TREND, BY REGION
5.10 KEY CONFERENCES & EVENTS DURING 2024-2025
5.11 KEY STAKEHOLDERS & BUYING CRITERIA
5.11.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
5.11.2 BUYING CRITERIA
5.12 REIMBURSEMENT ANALYSIS

6 HEMODIALYSIS MARKET, BY PRODUCT AND SERVICES (USD MILLION; 2022—2029)*
6.1 INTRODUCTION
6.2 HEMODIALYSIS MARKET , BY PRODUCTS AND SERVICES
6.2.1 HEMODIALYSIS MACHINES
6.2.1.1 CENTER-USE HEMODIALYSIS MACHINES
6.2.1.1 HOME-USE HEMODIALYSIS MACHINES
6.2.2 HEMODIALYSIS CONSUMABLES AND SUPPLIES
6.2.2.1 DIALYZERS
6.2.2.1.1 DIALYZERS MARKET , BY MATERIAL
6.2.2.1.1.1 SYNTHETIC DIALYZERS
6.2.2.1.1.2 CELLUSOSE BASED DIALYZERS
6.2.2.1.2 DIALYZERS MARKET , BY FLUX
6.2.2.1.2.1 HIGH FLUX DIALYZERS
6.2.2.1.2.2 LOW FLUX DIALYZERS .
6.2.2.2 BLOODLINES SETS AND TUBES
6.2.2.3 HEMODIALAYSIS CONCENTRATES/DIALYSATES
6.2.2.3.1 ALKALINE CONCENTRATES/DIALYSATES
6.2.2.3.2 ACIDIC CONCENTRATES/DIALYSATES
6.2.2.4 OTHER HEMODIALYSIS CONSUMABLES (ENDOTOXIN FILTERS, BICARBONATE CARTRIDGES, AV FISTULA NEEDLE AND BAGS)
6.2.3 HEMODIALYSIS SERVICES
6.3 HEMODIALYSIS MARKET BY MODALITY
6.3.1 CONVENTIONAL HEMODIALYSIS
6.3.2 SHORT DAILY HEMODIALYSIS
6.3.2 NOCTURNAL HEMODIALYSIS (NHD)
6.4 HEMODIALAYIS WATER TREATMENT SYSTEMS MARKET, BY TYPE
6.4.1 CENTRAL WATER DISINFECTANT SYSTEMS
6.4.2 PORTABLE DIALYSIS WATER DISINFECTANT SYSTEMS

7 PERITONEAL DIALYSIS MARKET, BY PRODUCT AND SERVICES (USD MILLION; 2022—2029)*
7.1 INTRODUCTION
7.2 PERITONEAL DIALYSIS MARKET , BY PRODUCTS AND SERVICES
7.2.1 PERITONEAL DIALYSIS MACHINES
7.2.2 PERITONEAL DIALYSIS CONCENTRATES/DIALYSATES
7.2.3 PERITONEAL DIALYSIS CATHETERS
7.2.4 PERITONEAL DIALYSIS TRANSFER SETS
7.2.5 OTHER PD PRODUCTS (INCLUDE PD ACCESSORIES SUCH AS TUBING SETS, DRAINAGE BAGS, DIALAYIS SOLUTION BAGS, DISCONNECT CAPS, BAG CONNECTORS, FLOW REGULATORS, AMONG OTHERS)
7.2.3 PERITONEAL DIALYSIS SERVICES
7.3 PERITONEAL DIALYSIS MARKET , BY MODALITY
7.3.1 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD)
7.3.2 AUTOMATED PERITONEAL DIALYSIS (APD)

8 HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY DISEASE INDICTION (USD MILLION; 2022—2029)*
8.1 INTRODUCTION
8.2 ACUTE KIDNEY INJURY (AKI)
8.3 CHRONIC KIDNEY DISEASE (CKD) AT END-STAGE.OR END-STAGE RENAL DISEASE (ESRD).
8.4 OTHER INDICATIONS (SEVERE ELECTROLYTE IMBALANCES, FLUID OVERLOAD, AND POISONING)

9 HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY END USER (USD MILLION; 2022—2029)*
9.1 INTRODUCTION
9.2 HOSPITALS
9.3 INDEPENDENT DIALYSIS CENTRES
9.4 HOME CARE SETTINGS
9.5 OTHER SETTINGS (SKILLED NURSING FACILITIES (SNFS), HEALTHCARE REHABILITATION CENTERS)

10 HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY REGION (USD MILLION; 2022—2029)*
10.1 NORTH AMERICA
10.1.1 RECESSION IMPACT
10.1.2 US
10.1.3 CANADA
10.2 EUROPE
10.2.1 RECESSION IMPACT
10.2.2 GERMANY
10.2.3 UK
10.2.4 FRANCE
10.2.5 ITALY
10.2.6 SPAIN
10.2.7 REST OF EUROPE
10.3 ASIA-PACIFIC
10.3.1 RECESSION IMPACT
10.3.2 JAPAN
10.3.3 CHINA
10.3.4 INDIA
10.3.5 SOUTH KOREA
10.3.6 AUSTRALIA
10.3.7 REST OF ASIA-PACIFIC
10.4 LATIN AMERICA
10.4.1 RECESSION IMPACT
10.4.2 BRAZIL
10.4.3 MEXICO
10.4.4 REST OF LATIN AMERICA
10.5 MIDDLE EAST AND AFRICA
10.5.1 RECESSION IMPACT
10.5.2 GCC COUNTRIES
10.5.3 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.3 REVENUE MAPPNG OF TOP PLAYERS (2023)
11.4 MARKET SHARE ANALYSIS FOR TOP 5 GLOBAL PLAYERS (IN TERMS OF % REVENUE, IN 2023)
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
11.5.1 STARS
11.5.2 EMERGING LEADERS .
11.5.3 PERVASIVE PLAYERS .
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.5.1 COMPANY FOOTPRINT
11.5.5.2 REGION FOOTPRINT .
11.5.5.3 PRODUCT FOOTPRINT
11.5.5.4 SERVICE FOOTPRINT
11.5.5.5 END USER FOOTPRINT
11.6 COMPANY EVALUATION MATRIX:STARTUP/SME EVALUATION MATRIX, 2023
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING STARTUPS/SMES,2023
11.6.5.1 DETAILED LIST OF KEY STARTUPS/SMEs
11.6.5.2 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMEs
11.7 COMPETITIVE SCENARIO AND TRENDS (2021-2024)
11.7.1 PRODUCT LAUNCHES
11.7.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
11.7.3 MERGERS AND ACQUISITIONS
11.7.4 EXPANSIONS
11.8 INVESTMENT AND FUNDING SCENARIO
11.9 PRODUCT COMPARITIVE ANALYSIS

12 COMPANY PROFILES**
(Business Overview, Products Offered, Industry-specific Developments for 2021-2023)***
12.1 KEY COMPANIES
12.1.1 FRESENIUS MEDICAL CARE AG & CO. KGAA
12.1.2 BAXTER.
12.1.3 B. BRAUN .
12.1.4 DAVITA INC.
12.1.5 ASAHI KASEI MEDICAL CO., LTD.
12.1.6 BECTON, DICKINSON AND COMPANY .
12.1.7 NIPRO CORPORATION .
12.1.8 NIKKISO CO., LTD.
12.1.9 DIAVERUM
12.1.10 MEDTRONIC
12.1.11 ROCKWELL MEDICAL, INC. .
12.1.12 AMERIWATER LLC
12.1.13 ISOPURE CORP
12.1.14 DIALIFE GROUP .
12.1.15 TORAY MEDICAL CO., LTD
12.1.16 JMS CO., LTD .
12.1.17 ATLANTIC BIOMEDICAL
12.1.18 TERUMO CORPORATION.
12.1.19 MERIT MEDICAL SYSTEMS.
12.1.20 COOK MEDICAL
12.2 OTHER PLAYERS
12.2.1 OUTSET MEDICAL
12.2.2 QUANTA DIALYSIS TECHNOLOGIES LTD
12.2.3 U.S. RENAL CARE, INC.
12.2.4 POLY MEDICURE LTD.
12.2.5 INNAVASC MEDICAL, INC
12.2.6 AMECATH MEDICAL TECHNOLOGIES
12.2.7 XYLEM.
12.2.8 ALLMED MEDICAL CARE HOLDINGS LIMITED.
12.2.9 SHENZHEN LANDWIND BIOMEDICAL TECHNOLOGY CO., LTD

13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS